The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States, 2000-2004
Abstract
BACKGROUND: Invasive group A Streptococcus (GAS) infection causes significant morbidity and mortality in the United States. We report the current epidemiologic characteristics of invasive GAS infections and estimate the potential impact of a multivalent GAS vaccine. METHODS: From January 2000 through December 2004, we collected data from Centers for Disease Control and Prevention's Active Bacterial Core surveillance (ABCs), a population-based system operating at 10 US sites (2004 population, 29.7 million). We defined a case of invasive GAS disease as isolation of GAS from a normally sterile site or from a wound specimen obtained from a patient with necrotizing fasciitis or streptococcal toxic shock syndrome in a surveillance area resident. All available isolates were emm typed. We used US census data to calculate rates and to make age- and race-adjusted national projections. RESULTS: We identified 5400 cases of invasive GAS infection (3.5 cases per 100,000 persons), with 735 deaths (case-fatality rate, 13.7%). Case-fatality rates for streptococcal toxic shock syndrome and necrotizing fasciitis were 36% and 24%, respectively. Incidences were highest among elderly persons (9.4 cases per 100,000 persons), infants (5.3 cases per 100,000 persons), and black persons (4.7 cases per 100,000 persons) and were stable over time. We estimate that 8950-11,500 cases of invasive GAS infection occur in the United States annually, resulting in 1050-1850 deaths. The emm types in a proposed 26-valent vaccine accounted for 79% of all cases and deaths. Independent factors associated with death include increasing age; having streptococcal toxic shock syndrome, meningitis, necrotizing fasciitis, pneumonia, or bacteremia; and having emm types 1, 3, or 12. CONCLUSIONS: GAS remains an important cause of severe disease in the United States. The introduction of a vaccine could significantly reduce morbidity and mortality due to these infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccines for the 21st Century: A Tool for Decisionmaking
Stratton, K. R., Durch, J. S., & Lawrence, R. S. (2013) · Cited by 440
Epidemiology of Invasive Group A Streptococcus Disease in the United States, 1995–1999
O’Brien, K. L., Beall, B., Barrett, N. L., Cieslak, P. R., Reingold, A., Farley, M. M., Danila, R., Zell, E. R., Facklam, R., Schwartz, B., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/341409 · Cited by 357
Self-citationSafety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers
McNeil, S. A., Halperin, S. A., Langley, J. M., Smith, B., Warren, A., Sharratt, G. P., Baxendale, D. M., Reddish, M. A., Hu, M. C., Stroop, S. D., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/444458 · Cited by 305
Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management
Steer, A. C., Lamagni, T., Curtis, N., & Carapetis, J. R. (2012) · Drugs · doi:10.2165/11634180-000000000-00000 · Cited by 273
Immunogenicity of a 26-Valent Group A Streptococcal Vaccine
Hu, M. C., Walls, M. A., Stroop, S. D., Reddish, M. A., Beall, B., & Dale, J. B. (2002) · Infection and Immunity · doi:10.1128/iai.70.4.2171-2177.2002 · Cited by 241
Self-citationKotloff, K. L., Corretti, M., Palmer, K., Campbell, J. D., Reddish, M. A., Hu, M. C., Wasserman, S. S., & Dale, J. B. (2004) · JAMA · doi:10.1001/jama.292.6.709 · Cited by 173
Invasive Group A Streptococcal Disease: Risk Factors for Adults
Factor, S. H., Levine, O. S., Schwartz, B., Harrison, L. H., Farley, M. M., McGeer, A., & Schuchat, A. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0908.020745 · Cited by 159
Self-citationThe Prevention of Invasive Group A Streptococcal Infections Workshop Participants (2002) · Clinical Infectious Diseases · doi:10.1086/342692 · Cited by 155
Risk Factors for Pediatric Invasive Group A Streptococcal Disease
Factor, S. H., Levine, O. S., Harrison, L. H., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1107.040900 · Cited by 88
Self-citationDey, N., McMillan, D. J., Yarwood, P., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/426443 · Cited by 80
Cited by
Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Walker, M. J., Barnett, T. C., McArthur, J. D., Cole, J. N., Gillen, C. M., Henningham, A., Sriprakash, K. S., Sanderson-Smith, M. L., & Nizet, V. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-13 · Cited by 908
Steer, A. C., Law, I., Matatolu, L., Beall, B. W., & Carapetis, J. R. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70178-1 · Cited by 537
Self-citationGram-positive toxic shock syndromes
Lappin, E., & Ferguson, A. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70066-0 · Cited by 433
Epidemiology of Severe Streptococcus pyogenes Disease in Europe
Lamagni, T. L., Darenberg, J., Luca-Harari, B., Siljander, T., Efstratiou, A., Henriques-Normark, B., Vuopio-Varkila, J., Bouvet, A., Creti, R., Ekelund, K., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00422-08 · Cited by 410
Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005–2012
Nelson, G. E., Pondo, T., Toews, K.-A., Farley, M. M., Lindegren, M. L., Lynfield, R., Aragon, D., Zansky, S. M., Watt, J. P., Cieslak, P. R., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw248 · Cited by 404
Self-citationRole of Pore-Forming Toxins in Bacterial Infectious Diseases
Los, F. C. O., Randis, T. M., Aroian, R. V., & Ratner, A. J. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00052-12 · Cited by 402
Molecular insight into invasive group A streptococcal disease
Cole, J. N., Barnett, T. C., Nizet, V., & Walker, M. J. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2648 · Cited by 377
Incidence of bloodstream infection: a review of population-based studies
Laupland, K. B. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12144 · Cited by 333
Molecular mechanisms regulating NETosis in infection and disease
Branzk, N., & Papayannopoulos, V. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0384-6 · Cited by 316
Fournier's Gangrene: Population Based Epidemiology and Outcomes
Sorensen, M. D., Krieger, J. N., Rivara, F. P., Broghammer, J. A., Klein, M. B., Mack, C. D., & Wessells, H. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.034 · Cited by 315
Clinical and Microbiological Characteristics of Severe Streptococcus pyogenes Disease in Europe
Luca-Harari, B., Darenberg, J., Neal, S., Siljander, T., Strakova, L., Tanna, A., Creti, R., Ekelund, K., Koliou, M., Tassios, P. T., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02155-08 · Cited by 300
Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management
Steer, A. C., Lamagni, T., Curtis, N., & Carapetis, J. R. (2012) · Drugs · doi:10.2165/11634180-000000000-00000 · Cited by 273
Dale, J. B., Penfound, T. A., Chiang, E. Y., & Walton, W. J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.005 · Cited by 258
Disparate Effects of Invasive Group A Streptococcus on Native Americans
Close, R. M., & McAuley, J. B. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2609.181169 · Cited by 14
Metadata
- Authors
- O'Loughlin, R. E., Roberson, A., Cieslak, P. R., Lynfield, R., Gershman, K., Craig, A., Albanese, B. A., Farley, M. M., Barrett, N. L., Spina, N. L., Beall, B., Harrison, L. H., Reingold, A., Beneden, C. V., & Active Bacterial Core Surveillance Team
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 45
- Issue
- 7
- Pages
- 853-862
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2040930422
- Cited by
- 499
- References
- 12
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.